Reactogenicity represents the physical manifestation of the inflammatory response to
vaccination, and can include injection-site pain, redness, swelling or induration at the …

The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …

Background An estimated 15% of girls aged 9–14 years worldwide have been vaccinated
against human papillomavirus (HPV) with the recommended two-dose or three-dose …

Background Human papillomavirus (HPV) vaccines are given as a two-dose schedule in
children aged 9–14 years, or as three doses in older individuals. We compared antibody …

To elucidate the role of innate responses in vaccine immunogenicity, we compared early
responses to hepatitis B virus (HBV) surface antigen (HBsAg) combined with different …

When administered as standard three-dose schedules, the licensed HPV prophylactic
vaccines have demonstrated extraordinary immunogenicity and efficacy. We summarize the …

The past 10 years have seen remarkable progress in the global scale‐up of human
papillomavirus (HPV) vaccinations. Forty‐three low‐and lower‐middle‐income countries …

Abstract Gardasil®(Merck) and Cervarix®(GlaxoSmithKline) both provide protection against
infection with Human Papillomavirus 16 (HPV16) and Human Papillomavirus 18 (HPV18) …

Background While PET using 18 F-FDG is most commonly used for imaging malignant
tumors, vaccination is known to cause transient inflammation of lymph nodes inducing …

Background Despite the availability of different therapeutic modalities, treatment of
recalcitrant common warts is still challenging. Cervarix (GlaxoSmithKline, Brentford, UK), a …